Pfizer is a drug manufacturers-general business based in the US. Pfizer stocks (PFE.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $43.96 – an increase of 1.08% over the previous week. Pfizer employs 78,500 staff and has a trailing 12-month revenue of around $46.4 billion.
How to buy Pfizer stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: PFE in this case.
- Research Pfizer stocks. The platform should provide the latest information available.
- Buy your Pfizer stocks. It's that simple.
What's in this guide?
- Can I buy shares in Pfizer?
- Has coronavirus impacted Pfizer shares?
- Pfizer shares summary
- Compare share dealing platforms
- Is Pfizer stock a buy or sell?
- Pfizer performance over time
- Can I short Pfizer shares?
- Is Pfizer suitable for ethical investing?
- Are Pfizer shares over-valued?
- Pfizer's financials
- How volatile are Pfizer shares?
- Does Pfizer pay a dividend?
- Have Pfizer shares ever split?
- Other common questions
How has Coronavirus impacted Pfizer's stock price?
Since the stock market crash in March caused by coronavirus, Pfizer's stock price has had significant positive movement.
Its last market close was $39.15, which is 8.76% up on its pre-crash value of $35.72 and 40.42% up on the lowest point reached during the March crash when the stocks fell as low as $27.88.
If you had bought $1,000 worth of Pfizer stocks at the start of February 2020, those stocks would have been worth $759.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,043.74.
Pfizer stock priceUse our graph to track the performance of PFE stocks over time.
Pfizer stocks at a glance
|Latest market close||$39.15|
|52-week range||$32.0506 - $43.74|
|50-day moving average||$40.0174|
|200-day moving average||$37.6813|
|Wall St. target price||$43.32|
|Dividend yield||$1.53 (3.55%)|
|Earnings per share (TTM)||$1.974|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Pfizer stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Pfizer price performance over time
|1 month (2021-07-02)||-1.46%|
|3 months (2021-05-04)||-2.00%|
Is Pfizer under- or over-valued?
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's P/E ratio
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Pfizer stocks trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
Pfizer's PEG ratio
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9736. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$16.8 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$46.4 billion|
|Operating margin TTM||25.8%|
|Gross profit TTM||USD$33.3 billion|
|Return on assets TTM||4.6%|
|Return on equity TTM||14.03%|
|Market capitalisation||USD$239.5 billion|
TTM: trailing 12 months
How to short and sell Pfizer stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "PFE.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 61.2 million Pfizer stocks held short by investors – that's known as Pfizer's "short interest". This figure is 2.5% up from 59.8 million last month.
There are a few different ways that this level of interest in shorting Pfizer stocks can be evaluated.
Pfizer's "short interest ratio" (SIR)
Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer stocks currently shorted divided by the average quantity of Pfizer stocks traded daily (recently around 19.8 million). Pfizer's SIR currently stands at 3.09. In other words for every 100,000 Pfizer stocks traded daily on the market, roughly 3090 stocks are currently held short.
However Pfizer's short interest can also be evaluated against the total number of Pfizer stocks, or, against the total number of tradable Pfizer stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfizer's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Pfizer stocks in existence, roughly 10 stocks are currently held short) or 0.011% of the tradable stocks (for every 100,000 tradable Pfizer stocks, roughly 11 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Pfizer.
Find out more about how you can short Pfizer stock.
Pfizer's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Pfizer's total ESG risk score
Total ESG risk: 33.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Pfizer's environmental score
Environmental score: 7/100
Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Pfizer's social score
Social score: 18.47/100
Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Pfizer's governance score
Governance score: 13.68/100
Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Pfizer's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||33.15|
|Total ESG percentile||60|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||3|
Pfizer stock dividends
Dividend payout ratio: 73.94% of net profits
Recently Pfizer has paid out, on average, around 73.94% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 3.59% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.53 per share.
Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Pfizer's most recent dividend payout was on 6 September 2021. The latest dividend was paid out to all shareholders who bought their stocks by 28 July 2021 (the "ex-dividend date").
Have Pfizer stocks ever split?
Pfizer stocks were split on a 1054:1000 basis on 16 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer stocks – just the quantity. However, indirectly, the new 5.1% lower stock price could have impacted the market appetite for Pfizer stocks which in turn could have impacted Pfizer's stock price.
Pfizer stock price volatility
Over the last 12 months, Pfizer's stocks have ranged in value from as little as $32.0506 up to $43.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.6763. This would suggest that Pfizer's stocks are less volatile than average (for this exchange).
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; Arvinas, Inc.; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Stocks similar to Pfizer
Pfizer in the news
UPDATE 2-Australia records one of its youngest COVID-19 deaths as Sydney outbreak grows
FDA aiming to give final approval to Pfizer vaccine by early next month: NY Times
FDA aims for full approval of Pfizer COVID-19 vaccine by Labor Day: report
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
How to buy Dole (DOLE) stock in Canada
Everything we know about the Dole IPO, plus information on how to buy in.